vs
Ascendis Pharma A/S（ASND）与传奇生物（LEGN）财务数据对比。点击上方公司名可切换其他公司
传奇生物的季度营收约是Ascendis Pharma A/S的1.0倍（$272.3M vs $267.3M），传奇生物同比增速更快（70.0% vs 42.3%），过去两年传奇生物的营收复合增速更高（92.7% vs 60.7%）
Ascendis Pharma A/S是一家聚焦内分泌疾病治疗领域的生物制药企业，核心业务覆盖生长激素疗法的研发、生产与商业化。其依托重组DNA技术生产的生长激素类处方药物，可用于治疗多种生长激素缺乏相关适应症，临床应用场景广泛。
传奇生物是金斯瑞生物科技旗下专注于生物科技领域的企业，金斯瑞2002年由章方良、王烨、王鲁泉等人于新泽西共同创立，总部位于中国，主要提供生命科学研究相关的仪器与服务，2015年在港交所上市，现任轮值首席执行官为邵炜慧。
ASND vs LEGN — 直观对比
营收规模更大
LEGN
是对方的1.0倍
$267.3M
营收增速更快
LEGN
高出27.7%
42.3%
两年增速更快
LEGN
近两年复合增速
60.7%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $267.3M | $272.3M |
| 净利润 | — | $-39.7M |
| 毛利率 | 90.5% | 58.4% |
| 营业利润率 | — | -16.0% |
| 净利率 | — | -14.6% |
| 营收同比 | 42.3% | 70.0% |
| 净利润同比 | — | 68.3% |
| 每股收益（稀释后） | — | $-0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASNDLEGN
| Q4 25 | $267.3M | — | ||
| Q3 25 | $230.7M | $272.3M | ||
| Q2 25 | $170.7M | $255.1M | ||
| Q1 25 | $109.0M | $195.1M | ||
| Q4 24 | $187.8M | — | ||
| Q3 24 | $62.5M | $160.2M | ||
| Q2 24 | $38.9M | $186.5M | ||
| Q1 24 | $103.6M | $94.0M |
净利润ASNDLEGN
| Q4 25 | — | — | ||
| Q3 25 | $-65.9M | $-39.7M | ||
| Q2 25 | $-42.0M | $-125.4M | ||
| Q1 25 | $-102.2M | $-100.9M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-107.1M | $-125.3M | ||
| Q2 24 | $-118.1M | $-18.2M | ||
| Q1 24 | $-141.5M | $-59.8M |
毛利率ASNDLEGN
| Q4 25 | 90.5% | — | ||
| Q3 25 | 89.5% | 58.4% | ||
| Q2 25 | 80.1% | 62.8% | ||
| Q1 25 | 82.6% | 64.4% | ||
| Q4 24 | 91.9% | — | ||
| Q3 24 | 80.6% | 67.2% | ||
| Q2 24 | 68.2% | 75.7% | ||
| Q1 24 | 92.1% | 47.8% |
营业利润率ASNDLEGN
| Q4 25 | — | — | ||
| Q3 25 | 5.1% | -16.0% | ||
| Q2 25 | -33.5% | — | ||
| Q1 25 | -103.2% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -167.3% | -43.9% | ||
| Q2 24 | -370.2% | — | ||
| Q1 24 | -51.2% | — |
净利率ASNDLEGN
| Q4 25 | — | — | ||
| Q3 25 | -28.5% | -14.6% | ||
| Q2 25 | -24.6% | -49.2% | ||
| Q1 25 | -93.7% | -51.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -171.5% | -78.2% | ||
| Q2 24 | -303.9% | -9.8% | ||
| Q1 24 | -136.6% | -63.6% |
每股收益（稀释后）ASNDLEGN
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.11 | ||
| Q2 25 | — | $-0.34 | ||
| Q1 25 | — | $-0.27 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.34 | ||
| Q2 24 | — | $-0.05 | ||
| Q1 24 | — | $-0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $665.3M | $278.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-175.8M | $1.0B |
| 总资产 | $1.4B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ASNDLEGN
| Q4 25 | $665.3M | — | ||
| Q3 25 | $582.2M | $278.9M | ||
| Q2 25 | $533.6M | $266.6M | ||
| Q1 25 | $559.4M | $441.7M | ||
| Q4 24 | $604.3M | — | ||
| Q3 24 | $675.6M | $459.3M | ||
| Q2 24 | $279.4M | $201.3M | ||
| Q1 24 | $345.9M | $897.6M |
股东权益ASNDLEGN
| Q4 25 | $-175.8M | — | ||
| Q3 25 | $-188.0M | $1.0B | ||
| Q2 25 | $-202.6M | $1.0B | ||
| Q1 25 | $-205.0M | $1.0B | ||
| Q4 24 | $-114.2M | — | ||
| Q3 24 | $-105.1M | $1.1B | ||
| Q2 24 | $-346.8M | $1.2B | ||
| Q1 24 | $-257.2M | $1.2B |
总资产ASNDLEGN
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.2B | $1.7B | ||
| Q2 25 | $1.2B | $1.7B | ||
| Q1 25 | $1.1B | $1.6B | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.2B | $1.7B | ||
| Q2 24 | $819.0M | $1.8B | ||
| Q1 24 | $866.7M | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.2M | $28.8M |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ASNDLEGN
| Q4 25 | $58.2M | — | ||
| Q3 25 | — | $28.8M | ||
| Q2 25 | — | $-13.0M | ||
| Q1 25 | $-15.5M | $-103.8M | ||
| Q4 24 | $-330.7M | — | ||
| Q3 24 | — | $-75.8M | ||
| Q2 24 | — | $-1.7M | ||
| Q1 24 | $-109.7M | $15.5M |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASND
暂无分部数据
LEGN
| Goods Or Services Transferred At Point In Time | $261.8M | 96% |
| Goods Or Services Transferred Over Time | $10.5M | 4% |
